No matter how grand a vision for a particular industry, disruption in practice is hard. This is especially true in industries like healthcare, which have long been resistant to software-driven change. But sometimes you can innovate within the bounds of the industry, using those very constraints to move it forward -- whether it’s understanding and working with the early adopters in healthcare to focusing on the bottomline. This conversation -- recorded at our recent a16z Summit in November 2017 -- between co-founder and CEO of Omada Health, Sean Duffy and CEO of Accolade, Rajeev Singh (moderated by a16z bio fund partner Jeff Low), considers how such innovation affects go-to-market strategies and pricing to measuring savings and the entire ecosystem of healthcare spend. As this generation of digital health tech companies begin to change the healthcare business -- and scale -- what effect are they having on the rising cost of heathcare overall, and the bottom line?
Starbucks supposedly spends more on healthcare than it does on coffee beans. And 20 years ago, says Rajeev Singh, CEO of Accolade, healthcare was 10% of GDP; today it’s 19% -- that's nearly one-fifths of our gross domestic product. So what tools do we have to address the high costs of health care, especially as stakeholders increasingly look for value-based care? This episode, recorded at our a16z inaugural Summit and moderated by Vijay Pande (a16z general partner on the bio fund) discusses approaches that combine new tech + people + data to address and improve healthcare. What are the macro trends driving innovations in the business of healthcare? And what will define the success of companies in this space? (Hint: it's not directly related to costs or healthcare reform.)